Advertisement
Picoplatin, the Company's lead product candidate, is a new generationplatinum chemotherapy agent with the potential to become a platform productaddressing multiple indications, administered either alone or in combinationwith other chemotherapy and targeted agents.
Advertisement
"We are continuing to execute on our clinical strategy, demonstrating thatpicoplatin is a platform product, with broad utility in multiple solid tumortypes," said Ronald Martell, president and chief operating officer of PoniardPharmaceuticals. "The data from these trials that we will present at ASCOshould illustrate the significant clinical value of picoplatin to patientswith a broad range of tumor types, including those with colorectal, prostateand ovarian cancer. These results should be of significant interest topotential partners. The data being presented adds to the growing body ofpicoplatin data in over 750 patients, including in patients with small celllung, colorectal, prostate and ovarian cancers."
In addition, Don S. Dizon, M.D., assistant professor ofobstetrics-gynecology and medicine at the Warren Alpert Medical School ofBrown University, will present data from a Phase 1 trial of picoplatin inpatients with ovarian cancer:
Poniard Investor Event
In addition to the picoplatin poster presentations, Poniard will host aninvestor event on Sunday, June 1, at 6:30 p.m. in Chicago. The event willfeature presentations and discussion with expert oncologists, including lungcancer expert Chandra Belani, M.D., of the University of Pittsburgh MedicalCenter; prostate cancer expert E. David Crawford, M.D., of the University ofColorado Health Sciences Center in Denver; and platinum therapy developer,Lloyd Kelland, Ph.D., of Cancer Research Technology and University CollegeLondon, in addition to members of Poniard's senior management. For moreinformation or to rsvp to the event, please email [email protected].
About Picoplatin
Picoplatin, the Company's lead platform product candidate, is a newgeneration platinum therapy with an improved safety profile relative toexisting platinum-based cancer therapies. Picoplatin is designed to overcomeplatinum resistance associated with chemotherapy in solid tumors, and is beingstudied in multiple cancer indications, combinations and formulations. Poniardis evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial,known as SPEAR (Study of Picoplatin Efficacy After Relapse), in small celllung cancer. This registration trial currently is being conducted under aSpecial Protocol Assessment (SPA) from the U.S. Food and Drug Administrationand is evaluating overall survival as the primary endpoint. The Company isalso evaluating intravenous picoplatin in an ongoing Phase 2 clinical trialfor the treatment of HRPC, and an ongoing Phase 2 clinical trial in patientswith patients with metastatic CRC. Oral picoplatin is being evaluated in aPhase 1 clinical trial in solid tumors. The oral formulation of picoplatin hasthe same active pharmaceutical ingredient as the intravenous formulation.Picoplatin has not been approved by any regulatory authority for use inhumans.
About Pon
